SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤GPS Phase 3 REGAL trial reached its 80th event; topline results expected this month
- ➤SLS009 Phase 2 newly diagnosed AML trial enrolled 40 of 80 patients
- ➤SLS009 relapsed/refractory AML data showed 54% ORR in monocytic patients
- ➤SLS009 relapsed/refractory AML data showed 57% ORR in TP53-mutated patients
- ➤Cash and equivalents totaled $134.7 million as of September 30, 2026
Expert Statements
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“We continue to execute across both of our clinical programs as we approach several important milestones”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“As announced earlier this month, we look forward to presenting our Phase 2 data in relapsed/refractory AML at the upcoming ASH in December.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication.”
Angelos Stergiou, President and Chief Executive Officer of SELLAS Life Sciences
“With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.”
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month -
- 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 -
Get started
Create a free account to read the full story.